Research Analysts Issue Forecasts for CLPT FY2025 Earnings

ClearPoint Neuro, Inc. (NASDAQ:CLPT) – Research analysts at B. Riley raised their FY2025 earnings estimates for shares of ClearPoint Neuro in a research note issued to investors on Thursday, February 27th. B. Riley analyst K. Bauser now forecasts that the company will earn ($0.58) per share for the year, up from their previous estimate of ($0.59). B. Riley has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for ClearPoint Neuro’s current full-year earnings is ($0.66) per share. B. Riley also issued estimates for ClearPoint Neuro’s Q4 2025 earnings at ($0.15) EPS.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The business had revenue of $7.77 million during the quarter, compared to analyst estimates of $8.23 million. ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%.

Separately, Lake Street Capital raised their price objective on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, January 21st.

ClearPoint Neuro Price Performance

Shares of NASDAQ CLPT opened at $13.55 on Monday. The stock has a market capitalization of $374.41 million, a price-to-earnings ratio of -19.64 and a beta of 1.03. ClearPoint Neuro has a 12 month low of $5.11 and a 12 month high of $19.22. The firm’s 50 day simple moving average is $16.62 and its 200-day simple moving average is $13.91.

Institutional Investors Weigh In On ClearPoint Neuro

Hedge funds and other institutional investors have recently made changes to their positions in the company. R Squared Ltd purchased a new position in shares of ClearPoint Neuro during the 4th quarter valued at approximately $32,000. Barclays PLC lifted its position in shares of ClearPoint Neuro by 24.3% during the 3rd quarter. Barclays PLC now owns 5,674 shares of the company’s stock valued at $64,000 after buying an additional 1,109 shares in the last quarter. AlphaQuest LLC purchased a new position in shares of ClearPoint Neuro during the 4th quarter valued at approximately $80,000. Tower Research Capital LLC TRC purchased a new position in shares of ClearPoint Neuro during the 4th quarter valued at approximately $93,000. Finally, JPMorgan Chase & Co. lifted its position in shares of ClearPoint Neuro by 58.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company’s stock valued at $110,000 after buying an additional 3,612 shares in the last quarter. Institutional investors and hedge funds own 30.08% of the company’s stock.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.